Danvers, Mass., October 6, 2005—ABIOMED, Inc. (NASDAQ: ABMD), a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart, today announced its schedule of events at the Cardiovascular Research Foundation’s (CRF) 17th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, being held in Washington, D.C. from October 16-21. ABIOMED will be exhibiting at booth #254 from October 17-19 and will be featured in numerous sessions throughout the meeting.

“The amount of interest we have received for ABIOMED and Impella technology at this year’s upcoming TCT has been unprecedented and recognizes the work we are doing to provide a robust family of circulatory support devices that can recover the heart,” said Michael R. Minogue, Chairman, CEO and President of ABIOMED. “We are excited to provide interventional cardiologists with information and demonstrations of the Impella Recover technology, designed to deliver minimally invasive circulatory support in the cath lab for such procedures as high risk angioplasty and stent placement.”

Below is an outline of ABIOMED’s presence at TCT.

Monday, October 17

• 8:30 am—Tentative live left main insertion of Impella® Recover® LP 2.5 by Dr. Eberhard Grube, Chief Cardiology/Angiology, Heart Center, Siegburg, Germany (note: all live cases are subject to change or cancellation).
• 3:30 pm—Oral Presentations, Room 147AB “Use of the Impella Percutaneous Ventricular Unloading Catheter in High Risk PCI,” Dr. Paolo Danna, Ospedale Luigi Sacco, Milan Italy.

  “Mechanical Circulatory Support Improves Recovery Outcomes in Profound Cardiogenic Shock Post AMI,” Dr. Mark Anderson, Associate Professor of Surgery and Chief Section of Cardiac Surgery, Robert Wood Johnson University Hospital, New Brunswick, New Jersey.

Tuesday, October 18

• 8:00 am—Tentative live Impella Case by Dr. Antonio Colombo from San Raffaele Hospital in Milan, Italy. Shown in the main arena (note: all live cases are subject to change or cancellation).
• 10:00 am or 11:30 am—Tentative live Impella Case in Masters Auditorium or Coronary Theater by Dr. Eulogio Garcia from Madrid, Spain (note: all live cases are subject to change or cancellation)
• 5:15 pm—Plenary Session II, Main Arena “Hemodynamic Support Can Save Lives: The Optimal Device-Based Approach in Patients with End-Stage CHF,” Dr. Donald Baim, Professor of Medicine, Harvard Medical School; Director, Center for Integration of Medicine and Innovative Technology, Brigham and Women’s Hospital, Boston.
• 7:00 pm—ABIOMED Co-Sponsored Event “Accelerating Device Based Therapy for Heart Failure and Recovery” with Keynote address by Dr. Martin Leon at the Renaissance Hotel, Ballroom. Presentations include: “The Future Role of Percutaneous Ventricular Assist Catheters in Interventional Cardiology” by Dr. Eberhard Grube; “Bridge to Recovery: Experience with ABIOMED Ventricular Assist Devices,” by Dr. Mark Anderson.
  

Wednesday, October 19

• 6:22 pm—Case Review Session, Room 149AB “Novel Hemodynamic Support During High Risk Coronary Anatomy,” Dr. J.P. Simao Henriques, Academic Medical Center, Amsterdam, Netherlands.

Thursday, October 20

• 2:40 pm—Oral Presentation, Room 150AB “LV Support Device Impella Increase Coronary Blood Flow in Patients with Compromised LV Undergoing Angioplasty,” Dr. Maurice Remmelink, Academic Medical Center, Amsterdam, Netherlands.

ABOUT TRANSCATHETER CARDIOVASCULAR THERAPEUTICS 2005
Transcatheter Cardiovascular Therapeutics (TCT), sponsored by the Cardiovascular Research Foundation(R), is a scientifically stimulating symposium for physicians and other health care professionals who specialize in the field of interventional vascular therapy. This year's event is scheduled for Oct. 16-21, 2005, Washington Convention Center, Washington, D.C. For more information, please visit http://www.tct2005.com.

ABOUT ABIOMED
Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB’-EE-O-MED”) is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the Impella® Recover™ minimally invasive cardiovascular support systems under CE Mark approval. The Company’s AbioCor® Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. For additional information please visit: www.abiomed.com.

IMPELLA DEVICES
Impella products are investigational devices limited by Federal Law solely to investigational use in the United States and are not yet available for sale in the United States

Contacts:
Liza Heapes
ABIOMED INC.
Media Relations
(978) 646-1668
mediarelations@abiomed.com

Investor Relations Contact:
Melody Carey
Rx COmmunications Group, LLC
(917) 322-2571
mcarey@rxir.com

FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of ABIOMED’s existing and new products, the Company’s progress toward commercial growth, and future opportunities. The Company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

###